Minireviews
Copyright ©The Author(s) 2017.
World J Clin Oncol. Aug 10, 2017; 8(4): 320-328
Published online Aug 10, 2017. doi: 10.5306/wjco.v8.i4.320
Table 1 Correlation between nivolumab activity and outcome and programmed cell death protein ligand 1 immunohistochemestry score
Author/studyMarker antibodyTumor typeTreatment linePD-L1 cutoffN ptsResponse (%)mPFS mo (95%CI)mOS mo (95%CI)
Nivolumab
Gettinger et al[8] Phase IDako 28-8NSCLC> 2≥ 5 %33153.3 (1.8-7.5)7.8 (5.6-21.7)
< 5%35141.8 (1.7-2.3)10.5 (5.2-14.8)
Rizvi et al[9] CM 063 Phase IIDako 28-8Squamous≥ 2≥ 5%2524NRNR
NSCLC< 5%5114NRNR
Brahmer et al[10] CM 017 Phase IIIDako 28-8Squamous> 1≥ 10%36193.7 (NR)11 (NR)
NSCLC< 10%81162.3 (NR)8.2 (NR)
≥ 5%42214.8 (NR)10 (NR)
< 5%75152.2 (NR)8.5 (NR)
≥ 1%63173.3 (NR)9.3 (NR)
< 1%54173.1 (NR)8.7 (NR)
Borgheai et al[11] CM 057 Phase IIIDako 28-8Non squamous> 1≥ 10%86375.0 (NR)19.9 (NR)
NSCLC< 10%145112.1 (NR)9.9 (NR)
≥ 5%95345.0 (NR)19.4 (NR)
< 5%136142.1 (NR)9.8 (NR)
≥ 1%123314.2 (NR)17.7 (NR)
< 1%10892.1 (NR)10.5 (NR)
Gettinger et al[12] CM 012 Phase IDako 28-8NSCLC1≥ 50%1250NRNR
< 50%3415NRNR
≥ 25%1844NRNR
< 25%2811NRNR
≥ 10%2040NRNR
< 10%2612NRNR
≥ 5%2631NRNR
< 5%2015NRNR
≥ 1%3228NRNR
< 1%1414NRNR
Rizvi et al[13] CM012 Phase IDako 28-8NSCLC1≥ 1%23486.0 (< 0.1+-21.8)20.2 (6.2-28.8+)
< 1%21435.2 (0.9+-28.7+)19.2 (4.5-29.7+)
Socinski et al[14] CM 026 Phase IIIDako 28-8NSCLC1≥ 5%NR76.80NRNR
< 5%NRNRNRNR
≥ 25%NR48.70NRNR
< 25%NRNRNRNR
≥ 50%NR32.50NRNR
< 50%NRNRNRNR
≥ 75%NR20.70NRNR
< 75%NRNRNRNR